Ana Sayfa
Piyasalar
Grafikler ve Fikirler
Algo
Haberler
Store
Aracı Kurumlar
İndir
Ekonomik Takvim
Alım-Satım Sinyalleri
Web Terminali
Heatmap
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
NPCE
#2908
Neuropace, Inc. Common Stock
15.350
0
USD
+3.16%
Sektör:
Sağlık Hizmetleri
Baz:
USD
Kar Para Birimi:
USD
Günlük Aralık
Yıllık Aralık
Günlük Değişim
+3.16%
Aylık Değişim
+7.34%
6 aylık değişim
+45.09%
Yıllık Değişim
+45.09%
Önceki Kapanış
14.880
0
Open
15.350
0
Bid
Ask
Low
15.350
0
High
15.350
0
Hacim
73
Piyasalar
ABD Borsası
Sağlık Hizmetleri
NPCE
Open full chart
Financials
Overview
Rapor
Statistics
Quarterly
Annual
Value
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
24.47 M
25.1 M
28.34 M
32.56 M
33.67 M
—
Valuation ratios
Enterprise value
277.33 M
99.31 M
331.55 M
424.26 M
568.96 M
1.83 B
Price to earnings ratio
-4.65
-0.75
-7.7
-12.03
-23.39
-65.9
Price to sales ratio
3.71
0.78
3.86
4.08
5.05
16.7
Price to cash flow ratio
-6.81
-0.96
-12.83
-18.16
-45.91
-107.42
Price to book ratio
2.28
1.02
12.24
40.67
26.55
44.03
Enterprise value to EBITDA ratio
-9.82
-0.73
-9.7
-16.52
-31.4
-87.25
Profitability ratios
Return on assets %
-0.27
-0.41
-0.31
-0.29
-0.2
-0.2
Return on equity %
-0.49
-1.35
-1.6
-3.39
-1.13
-1.05
Return on invested capital %
-688.48
-593.64
-275.04
-239.11
-225.29
-215.16
Gross margin %
74
71.38
73.56
73.94
77.23
308.87
Operating margin %
-52.54
-89.62
-41.54
-27.12
-16.34
-68.02
EBITDA margin %
-51.29
-88.46
-40.84
-26.58
-15.87
-66.1
Net margin %
-79.85
-103.43
-50.38
-33.97
-21.47
-89.08
Liquidity ratios
Quick ratio
13.44
8.02
5.02
4.48
4.33
18.49
Current ratio
14.28
8.9
5.71
5.37
5.28
22.24
Inventory turnover
1.5
1.49
1.65
1.69
1.5
1.45
Asset turnover
0.34
0.37
0.59
0.79
1
0.94
Solvency ratios
Debt to assets ratio
0.37
0.61
0.67
0.77
0.67
2.67
Debt to equity ratio
0.68
2.01
3.51
9.15
3.72
14.26
Long term debt to total assets ratio
0.37
0.46
0.53
0.63
0.56
2.2
Long term debt to total equity ratio
0.68
1.52
2.76
7.43
3.09
11.75
Per share metrics
Operating cash flow per share
-1.48
-1.5
-0.76
-0.62
-0.34
-0.34
EBIT per share
-1.43
-1.66
-1.05
-0.74
-0.5
-0.5
EBITDA per share
-1.4
-1.64
-1.03
-0.73
-0.48
-0.49
Total debt per share
3
2.84
2.8
2.52
2.16
8.81
Cash per share
6.96
3.15
2.57
1.81
1.87
7.67
Net current asset value per share
8
3.97
3.59
2.79
2.87
11.7
Tangible book value per share
4.43
1.41
0.8
0.28
0.58
2.5
Working capital per share
7.44
3.53
2.96
2.27
2.33
9.58
Book value per share
4.43
1.41
0.8
0.28
0.58
2.5
Haberler
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026
NPCE RNS System Explained: Growth Drivers and Setup for 2026
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand
Neuropace CMO 399 bin dolarlık hisse sattı
Neuropace (NPCE) chief medical officer sells $399k in stock
NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript
NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates
NeuroPace hisseleri 4Ç geliriyle tahminleri aştı, %15 yükseldi
NeuroPace beats estimates as Q4 revenue surges 24%, sending shares up 15%
Neuropace kazancı $0,10 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek
Neuropace earnings beat by $0.10, revenue topped estimates
LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates